Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.prnewswire.com/news-releases/kazia-therapeutics-reports-early-conclusion-of-clinical-trial-after-reaching-primary-endpoint-302067134.html
https://www.prnewswire.com/news-releases/kazia-continues-board-renewal-with-two-new-appointments-302038014.html
https://www.prnewswire.com/news-releases/kazia-therapeutics-announces-closing-of-2-million-registered-direct-offering-302006773.html
https://www.prnewswire.com/news-releases/kazia-therapeutics-announces-2-million-registered-direct-offering-302003040.html
https://www.prnewswire.com/news-releases/kazia-provides-overview-of-paxalisib-related-presentations-from-the-society-of-neuro-oncology-2023-annual-meeting-301994318.html
https://www.prnewswire.com/news-releases/kazia-announces-receipt-of-nasdaq-minimum-bid-notification-301994026.html
https://www.prnewswire.com/news-releases/kazia-announces-the-release-of-pnoc022-clinical-study-abstract-highlighting-paxalisib-in-diffuse-midline-glioma-patients-ahead-of-the-society-of-neuro-oncology-2023-annual-meeting-301989147.html
https://www.prnewswire.com/news-releases/kazia-announces-publication-in-molecular-cancer-therapeutics-highlighting-paxalisib-preclinical-data-in-melanoma-301984365.html
https://www.prnewswire.com/news-releases/kazia-therapeutics-provides-preliminary-update-from-ongoing-phase-2-study-of-paxalisib-in-primary-cns-lymphoma-301973774.html
https://www.prnewswire.com/news-releases/kazia-therapeutics-announces-clinical-data-at-esmo-2023-from-ongoing-phase-1-evt801-study-301963732.html